An Exploratory Study of RO4929097 in Patients With Recurrent or Refractory Non-Small Cell Lung Cancer
Status:
Completed
Trial end date:
2010-08-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the anti-tumour activity, safety and tolerability of RO4929097 as
monotherapy in patients with recurrent or refractory non-small cell lung cancer. Patients
will receive oral doses of RO4929097 of 80mg (cohort 1) or recommended Phase II dose (cohort
2) on a 3 days on 4 days off schedule. Anticipated time on study treatment is until disease
progression or unacceptable toxicity. Target sample size is <50.